Oxytocin receptor antagonism in migraine: a randomized, double-blind, placebo-controlled provocation study

What Was Tested

The paper reports a study of Oxytocin in the context of migraine, published as a randomized controlled trial.

Oxytocin has been implicated in migraine pathophysiology through its roles in pain modulation and vascular regulation.

Its receptors are present in migraine-related brain regions and cerebral vessels and interact with key migraine mediators such as calcitonin gene-related peptide (CGRP).

This study examined whether acute oxytocin receptor blockade provokes migraine attacks or alters cerebrovascular function.

Why It Was Studied

DRKS - Deutsches Register Klinischer Studien: DRKS00033341.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Women used continuous hormonal contraception to ensure stable hormone levels.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Oxytocin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Oxytocin group a baseline to be compared against.

In the crossover set-up each of the participants took both Oxytocin and the comparison in turn, acting as their own control.

The primary endpoint was the incidence of migraine-like attacks in WM within 12 h post-infusion.

Secondary endpoints included the incidence and intensity of any headache and vascular responses.

What Was Measured

The subject headings attached to it are Migraine Disorders, Receptors, Oxytocin, Vasotocin and Hormone Antagonists.

Author keywords: Hypothalamus, Trigger, Vascular response and Vasodilatation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin in people with migraine.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (The journal of headache and pain), a journal based in England.

More context: the Oxytocin compound page, Migraine research.